HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomark...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/7/1336 |
| _version_ | 1797212801975975936 |
|---|---|
| author | Magdalena K. Scheck Ralf D. Hofheinz Sylvie Lorenzen |
| author_facet | Magdalena K. Scheck Ralf D. Hofheinz Sylvie Lorenzen |
| author_sort | Magdalena K. Scheck |
| collection | DOAJ |
| description | Despite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments. |
| first_indexed | 2024-04-24T10:48:10Z |
| format | Article |
| id | doaj.art-baea2f6b1d4c422c83ca71182a6c7ae8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-04-24T10:48:10Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-baea2f6b1d4c422c83ca71182a6c7ae82024-04-12T13:16:04ZengMDPI AGCancers2072-66942024-03-01167133610.3390/cancers16071336HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future DevelopmentsMagdalena K. Scheck0Ralf D. Hofheinz1Sylvie Lorenzen2Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, 81675 Munich, GermanyMannheim Cancer Center, Universitätsklinikum Mannheim, 68167 Mannheim, GermanyKlinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar der TU München, 81675 Munich, GermanyDespite a decreasing incidence in Western countries, gastric cancer is among the most common cancer subtypes globally and is associated with one of the highest tumor-related mortality rates. Biomarkers play an increasing role in the treatment against gastric cancer. HER2 was one of the first biomarkers that found its way into clinical practice. Since the ToGA trial, trastuzumab has been part of first-line palliative chemotherapy in metastatic or unresectable gastric cancer. HER2-targeting agents, such as the tyrosine kinase inhibitor lapatinib, the antibody drug conjugate (ADC) trastuzumab-emtansine or dual HER2 inhibition (pertuzumab and trastuzumab), have been investigated in the second-line setting but led to negative study results. More recently, the ADC trastuzumab-deruxtecan was authorized after the failure of trastuzumab-based treatment. However, further improvements in HER2-directed therapy are required as resistance mechanisms and HER2 heterogeneity limit the existing treatment options. This review aims to give an overview of the current standard-of-care HER2-directed therapy in gastric cancer, as well as its challenges and future developments.https://www.mdpi.com/2072-6694/16/7/1336HER2gastric cancertrastuzumabT-DXdtargeted therapy |
| spellingShingle | Magdalena K. Scheck Ralf D. Hofheinz Sylvie Lorenzen HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments Cancers HER2 gastric cancer trastuzumab T-DXd targeted therapy |
| title | HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments |
| title_full | HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments |
| title_fullStr | HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments |
| title_full_unstemmed | HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments |
| title_short | HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments |
| title_sort | her2 positive gastric cancer and antibody treatment state of the art and future developments |
| topic | HER2 gastric cancer trastuzumab T-DXd targeted therapy |
| url | https://www.mdpi.com/2072-6694/16/7/1336 |
| work_keys_str_mv | AT magdalenakscheck her2positivegastriccancerandantibodytreatmentstateoftheartandfuturedevelopments AT ralfdhofheinz her2positivegastriccancerandantibodytreatmentstateoftheartandfuturedevelopments AT sylvielorenzen her2positivegastriccancerandantibodytreatmentstateoftheartandfuturedevelopments |